Helus Pharma Chief Medical Officer to Speak at H.C. Wainwright Neuro Perspectives Conference

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference is scheduled for June 15-16, 2026, and the fireside chat will be available on demand starting June 15 at 7:00 a.m. EDT. This engagement provides a platform for Helus Pharma to discuss its pipeline and clinical data with investors and industry experts.

The announcement is significant because it underscores Helus Pharma's commitment to addressing the large unmet need in mental health treatment. The company is developing proprietary NSAs designed to activate serotonin pathways that promote neuroplasticity, potentially offering durable improvements for conditions like depression and anxiety. Helus Pharma's lead candidate, HLP003, is in Phase 3 clinical development for major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. These programs represent a shift toward more targeted and effective treatments for mental health disorders, which affect millions worldwide.

The H.C. Wainwright conference is a key event for biotech and pharmaceutical companies to showcase their advancements. For Helus Pharma, participation signals confidence in its clinical data and strategic direction. The fireside chat will likely cover the company's research portfolio, including its extensive pipeline of investigational NSAs. Investors and stakeholders can access the on-demand recording to gain insights into Helus Pharma's progress and future milestones. The company operates in Canada, the United States, the United Kingdom, and Ireland, with a focus on bringing innovative therapies to market. For more information about Helus Pharma, visit its website at www.helus.com or follow the team on social media platforms.

This conference participation comes at a critical time for the mental health industry, as demand for novel treatments continues to grow. Helus Pharma's NSA platform has the potential to change the treatment landscape by offering therapies that target the underlying mechanisms of mental health conditions. The company's Breakthrough Therapy Designation for HLP003 highlights the FDA's recognition of its potential to address significant unmet needs. As Helus Pharma advances its clinical programs, the outcomes of these studies will be closely watched by the medical community and investors alike.